MARKETSPERPSLIVE98
Cash
Portfolio
TrendingElectionsPoliticsSportsCultureCryptoCommoditiesClimateEconomicsMentions

Finance

Tech & Science
PredictLive98AccountSocial
Product
Kalshi ProPerpetual FuturesMarketsIncentive programInstitutionsAPI & developers
Company
AboutKalshi ResearchBlogCareersPolicy CenterBrand Kit
Help
Help CenterFAQFee scheduleTrading hoursRegulatoryTrust Center
© 2026 Kalshi Inc. · All rights reserved
PrivacyData Terms of ServiceTrading ProhibitionsFAQ for Finance Professionals
Trading on Kalshi involves risk and may not be appropriate for all. Members risk losing their cost to enter any transaction, including fees. You should carefully consider whether trading on Kalshi is appropriate for you in light of your investment experience and financial resources. Any trading decisions you make are solely your responsibility and at your own risk. Information is provided for convenience only on an "AS IS" basis. Past performance is not necessarily indicative of future results. Kalshi is subject to U.S. regulatory oversight by the CFTC.

Industries

All markets
Public Companies Hub
Indices
Foreign Exchange
Interest Rates
Company metrics
Company news
Industries
Biotech
Ski Resorts
Advertising Spend
Match Ups
Companies
Markets
Biotech

FDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (this year)

Yes
--
No
13.4x
$3,409 vol1 market
Biotech

FDA decision: Saroglitazar by Zydus Therapeutics (this year)

Yes
1.31x
No
2.98x
$1,143 vol1 market
Biotech

FDA decision: Venglustat by Sanofi (this year)

Yes
1.16x
No
4.51x
$816 vol1 market
Biotech

FDA decision: Ivonescimab by Summit Therapeutics (this year)

Yes
1.38x
No
2.89x
$8,576 vol1 market
Biotech

FDA decision: Bepirovirsen by GlaxoSmithKline (this year)

Yes
1.01x
No
15.6x
$4,044 vol1 market
Biotech

FDA decision: BBP-418 by Ml Bio Solutions Inc. (this year)

Yes
1.06x
No
7.85x
$831 vol1 market
Biotech

FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (this year)

Yes
1.05x
No
8.56x
$2,814 vol1 market